Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen

Contraception

Volumn 84, Issue 1, 2011, Pages 81-86

  Marr, Joachim ^a   Niknian, Minoo ^b   Shulman, Lee P ^c   Lynen, Richard ^d  

^a BAYER PHARMA AG   (Germany)

^b Nabi Biopharmaceuticals   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Bayer HealthCare Pharmaceuticals Inc   (United States)

Author keywords

Daily Record of Severity of Problems; Drospirenone; Ethinylestradiol; Oral contraceptives; Premenstrual disorders; Premenstrual dysphoric disorder

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; PLACEBO;

ADULT; ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMOTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ORAL CONTRACEPTION; PHASE 3 CLINICAL TRIAL; PREMENSTRUAL DYSPHORIC DISORDER; RANDOMIZED CONTROLLED TRIAL; WATER RETENTION; WITHDRAWAL SYNDROME;

ADULT; ANDROSTENES; BODY COMPOSITION; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; EMOTIONS; ETHINYL ESTRADIOL; FEEDING BEHAVIOR; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; PREMENSTRUAL SYNDROME; REPRODUCTIVE CONTROL AGENTS;

EID: 79958766080     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.10.010     Document Type: Article

References (29)

1. Alvir JM, Thys-Jacobs S. Premenstrual and menstrual symptom clusters and response to calcium treatment. Psychopharmacol Bull 1991;27:145-8.
2. Kessel B. Premenstrual syndrome. Advances in diagnosis and treatment. Obstet Gynecol Clin North Am 2000;27:625-39.
3. American Psychiatric Association. Premenstrual dysphoric disorder. In Diagnostic statistical and manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association; 2000, pp. 771-4.
4. Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007;23:123-30. (Pubitemid 46570210)
5. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003;28(Suppl 3):1-23. (Pubitemid 39658675)
6. Guille C, Spencer S, Cavus I, Epperson CN. The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment. Epilepsy Behav 2008;13:12-24.
7. Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: effect on symptom severity and type in a controlled trial. Obstet Gynecol 1994;84:779-86. (Pubitemid 24329844)
8. Hussain SY, Massil JH, Matta WH, Shaw RW, O'Brien PM. Buserelin in premenstrual syndrome. Gynecol Endocrinol 1992;6:57-64.
9. Muse KN, Cetel NS, Futterman LA, Yen SC. The premenstrual syndrome. Effects of "medical ovariectomy". N Engl J Med 1984;311:1345-9.
10. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990;162:105-9. (Pubitemid 20055432)
11. Casson P, Hahn PM, Van Vugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990;162:99-105. (Pubitemid 20055431)
12. Hammarback S, Ekholm UB, Backstrom T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol (Copenh) 1991;125:132-7.
13. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-30. (Pubitemid 38056418)
14. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6. (Pubitemid 30045651)
15. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21. (Pubitemid 41676830)
16. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501. (Pubitemid 41208780)
17. Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001;104:110-6. (Pubitemid 32656086)
18. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32. (Pubitemid 33150508)
19. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch WomensMent Health 2006;9:41-9. (Pubitemid 43088573)
20. Derman O, Kanbur NO, Tokur TE, Kutluk T. Premenstrual syndrome and associated symptoms in adolescent girls. Eur J Obstet Gynecol Reprod Biol 2004;116:201-6. (Pubitemid 39195135)
21. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278:983-8.
22. Dennerstein L, Lehert P, Backstrom TC, Heinemann K. Premenstrual symptoms - severity, duration and typology: an international cross-sectional study. Menopause Int 2009;15:120-6.
23. Dennerstein L, Lehert P, Backstrom TC, Heinemann K. The effect of premenstrual symptoms on activities of daily life. Fertil Steril 2010;94:1059-64.
24. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-76.
25. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol 1996;16:3-8. (Pubitemid 26059162)
26. Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-44. (Pubitemid 35246128)
27. Halbreich U, O'Brien PM, Eriksson E, Backstrom T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs 2006;20:523-47.
28. Landen M, Nissbrandt H, Allgulander C, Sorvik K, Ysander C, Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology 2007;32:153-61. (Pubitemid 44967793)
29. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 2004;161:343-51.